

# PARP Inhibitor Pan-Tumour Clinical Resource: Supporting Oncology Pharmacists in Managing Breast, Prostate, Ovarian, and Pancreatic Cancers

Friday, April 4, 2025 | 7:15 AM – 8:45 AM PT  
Victoria Conference Centre, Victoria, BC

## Speakers

**Glenn Myers, BScPharm, ACPR, RPh**  
Clinical Resource Pharmacist,  
Hematology/Oncology,  
Dr. Sheldon H. Rubin Oncology Clinic,  
Horizon Health Network  
Adjunct Professor, College of Pharmacy,  
Dalhousie University, Halifax



**Aalok Kumar, MD, MHSc, FRCPC**  
Department Head,  
Medical Oncology, BC Cancer Surrey  
Clinical Assistant Professor,  
Faculty of Medicine, UBC



## Learning Objectives

At the end of this session, participants will be able to:

- Explain the role of PARP inhibitor therapy in the treatment of breast, prostate, ovarian and pancreatic cancers
- Understand the similarities and differences in the clinical management of patients with different solid tumours who are receiving PARP inhibitor therapy
- Implement proactive and reactive toxicity management strategies from the CANO-endorsed PARP Inhibitor Clinical Resource to optimize tolerability and clinical benefit from PARP inhibitor therapy